Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands | BMJ Open Diabetes Research & Care

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands - January 01, 2020

XML

Emerging Technologies, Pharmacology and Therapeutics

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Hunt B, Malkin SJP, Moes RGJ, et al

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

BMJ Open Diabetes Research and Care 2019;7:e000705. doi: 10.1136/bmjdrc-2019-000705